BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE epsilon 4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.
BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE epsilon 4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.
Authors: H C Hendrie; B O Osuntokun; K S Hall; A O Ogunniyi; S L Hui; F W Unverzagt; O Gureje; C A Rodenberg; O Baiyewu; B S Musick Journal: Am J Psychiatry Date: 1995-10 Impact factor: 18.112
Authors: Gloria Lena Vega; Myron F Weiner; Anne M Lipton; Klaus Von Bergmann; Dieter Lutjohann; Carol Moore; Doris Svetlik Journal: Arch Neurol Date: 2003-04
Authors: Peter P Zandi; D Larry Sparks; Ara S Khachaturian; Joann Tschanz; Maria Norton; Martin Steinberg; Kathleen A Welsh-Bohmer; John C S Breitner Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Aina Hognestad; Pål Aukrust; Ragnhild Wergeland; Oddvar Stokke; Lars Gullestad; Anne Grete Semb; Torbjørn Holm; Arne K Andreassen; John K Kjekshus Journal: Clin Cardiol Date: 2004-04 Impact factor: 2.882
Authors: Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer Journal: J Gerontol A Biol Sci Med Sci Date: 2002-07 Impact factor: 6.053
Authors: Cynthia M Carlsson; David M Nondahl; Barbara E K Klein; Patrick E McBride; Mark A Sager; Carla R Schubert; Ronald Klein; Karen J Cruickshanks Journal: Alzheimer Dis Assoc Disord Date: 2009 Jan-Mar Impact factor: 2.703
Authors: N L Campbell; M A Boustani; K A Lane; S Gao; H Hendrie; B A Khan; J R Murrell; F W Unverzagt; A Hake; V Smith-Gamble; K Hall Journal: Neurology Date: 2010-07-13 Impact factor: 9.910
Authors: Sujuan Gao; James T Nguyen; Hugh C Hendrie; Frederick W Unverzagt; Ann Hake; Valerie Smith-Gamble; Kathleen Hall Journal: J Am Geriatr Soc Date: 2010-11-04 Impact factor: 5.562
Authors: Abhishek S Chitnis; Rajender R Aparasu; Hua Chen; Mark E Kunik; Paul E Schulz; Michael L Johnson Journal: Drugs Aging Date: 2015-09 Impact factor: 3.923
Authors: Anthony D Heymann; Ramit Ravona-Springer; Erin L Moshier; James Godbold; Michal Schnaider Beeri Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Colin R Dormuth; Amanda R Patrick; William H Shrank; James M Wright; Robert J Glynn; Jenny Sutherland; M Alan Brookhart Journal: Circulation Date: 2009-04-06 Impact factor: 29.690